Rapid determination of the presence of EGFR mutations with DNA-based nanocalipers.

Abstract excerpt

Selecting 1st-line treatment for lung cancer is currently a binary choice, either chemotherapy or targeted medicine, depending on whether EGFR mutations exist. Next-generation sequencing is fully capable of accurately identifying EGFR mutations and guiding the usage of tyrosine kinase inhibitors, but it is highly expensive. Moreover, as the sequencing is not helpful for patients with wild-type EGFR, the long wait...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to DNA
• Share to ErbB Receptors
• Share to Lung